2015 Press Releases

Keyword Search
 
2017 | 2016 | 2015
DateTitle  
12/02/15Tokai Pharmaceuticals to Present at the Oppenheimer 26th Annual Healthcare Conference
BOSTON--(BUSINESS WIRE)--Dec. 2, 2015-- Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today announced that Jodie Morrison, President and Chief Executive Officer, will present at the Oppenheimer 26th Annual Healthcare Conference on Wednesday, December 9, 2015 at 9:10am ET, at The Westin Grand Central in N... 
Download PDFPrinter Friendly Version
11/10/15Tokai Pharmaceuticals Reports Third Quarter 2015 Financial Results
Continued Progress in ARMOR3-SV Phase 3 Trial; Commercial Strategy in Development BOSTON--(BUSINESS WIRE)--Nov. 10, 2015-- Tokai Pharmaceuticals Inc. (NASDAQ: TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today reported results for the quarter ended September 30, 2015. “This was an important quarter of progress for Tokai,” said... 
Download PDFPrinter Friendly Version
11/07/15Tokai Announces Presentation of Galeterone Data in Models of the AR-V7 Splice Variant at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
BOSTON--(BUSINESS WIRE)--Nov. 7, 2015-- Tokai Pharmaceuticals Inc. (NASDAQ: TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today announced the presentation of new data highlighting the anti-tumor activity of galeterone in multiple preclinical tumor models expressing the androgen receptor (AR) splice variant AR-V7 at the AACR-NCI-EORTC Internationa... 
Download PDFPrinter Friendly Version
11/05/15Tokai Pharmaceuticals to Present at Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--Nov. 5, 2015-- Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally-driven diseases, today announced that management will present at three upcoming investor conferences: 2015 Credit Suisse Healthcare Conference on Wednesday, November 11, 2015 at 2:30pm MT, at The Phoenician in Phoeni... 
Download PDFPrinter Friendly Version
10/15/15Tokai Pharmaceuticals to Present at 14th Annual BIO Investor Forum
BOSTON--(BUSINESS WIRE)--Oct. 15, 2015-- Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally-driven diseases, today announced that Jodie Morrison, President and Chief Executive Officer, will present at the 14th Annual BIO Investor Forum on Wednesday, October 21, 2015 at 11:00 a.m. PT, at the Parc 55 Hotel in San Francisco. ... 
Download PDFPrinter Friendly Version
10/08/15Tokai Pharmaceuticals Announces Presentation of AR-V7 Clinical Trial Assay at the Prostate Cancer Foundation’s Annual Scientific Retreat
BOSTON--(BUSINESS WIRE)--Oct. 8, 2015-- Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally-driven diseases, today announced that a detailed overview of its AR-V7 clinical trial assay will be presented tonight at a poster session during the 22nd Annual Prostate Cancer Foundation Scientific Retreat in Washington, DC. T... 
Download PDFPrinter Friendly Version
09/16/15Tokai Pharmaceuticals Augments Commercialization Capabilities through Appointment of Lisa Taylor as Senior Vice President, Commercial Development
BOSTON--(BUSINESS WIRE)--Sep. 16, 2015-- Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally-driven diseases, today announced the appointment of Lisa Taylor as Senior Vice President, Commercial Development. Ms. Taylor brings over two decades of experience in biopharmaceutical marketing, and was a member of the launch team for ... 
Download PDFPrinter Friendly Version
08/12/15Tokai Pharmaceuticals Reports Second Quarter 2015 Results
Pivotal Phase 3 Trial of Galeterone in AR-V7 Positive Metastatic Castration-Resistant Prostate Cancer on Track for Topline Data by End of 2016 BOSTON--(BUSINESS WIRE)--Aug. 12, 2015-- Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI), a biopharmaceutical company focused on developing and commercializing proprietary therapies for prostate cancer and other hormonally driven diseases, today reported results for the quarter ended June 30, 2015. ... 
Download PDFPrinter Friendly Version
06/24/15Tokai Pharmaceuticals Announces Initiation of Phase 3 ARMOR3-SV Trial of Galeterone in AR-V7 Positive Metastatic Castration-Resistant Prostate Cancer
ARMOR3-SV Represents the First Precision Medicine-Based Pivotal Clinical Trial in Prostate Cancer; Topline Data Expected by the End of 2016 AR-V7 Clinical Trial Assay Components Finalized BOSTON--(BUSINESS WIRE)--Jun. 24, 2015-- Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI), a biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally-driven diseases, today announced the initiation of ARMOR3-SV... 
Download PDFPrinter Friendly Version
06/18/15Tokai Pharmaceuticals to Present at 2015 JMP Securities Life Sciences Conference
BOSTON--(BUSINESS WIRE)--Jun. 18, 2015-- Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI), a biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally-driven diseases, today announced that Lee Kalowski, Chief Financial Officer, will present at the JMP Securities Life Sciences Conference on Wednesday, June 24, 2015 at 12:30 pm ET, at The St. Regis New York in New York City. A live webcast of th... 
Download PDFPrinter Friendly Version
05/30/15Tokai Pharmaceuticals Announces Presentation at the 2015 ASCO Annual Meeting
Poster Highlights Protocol and Rationale for ARMOR3-SV, a Pivotal Trial of Galeterone in Patients with AR-V7 Positive Castration-Resistant Prostate Cancer ARMOR3-SV Remains on Track to Begin 2Q 2015, with Topline Data Expected by End of 2016 BOSTON--(BUSINESS WIRE)--May 30, 2015-- Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI), a biopharmaceutical company focused on developing novel therapies for prostate cancer and other ... 
Download PDFPrinter Friendly Version
05/28/15Tokai Pharmaceuticals to Present at Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--May 28, 2015-- Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI), a biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally-driven diseases, today announced that it will present at two upcoming investor conferences: Lee Kalowski, Chief Financial Officer, will present at the Jefferies 2015 Healthcare Conference on Thursday, June 4, 2015 at 2:00pm ET, at t... 
Download PDFPrinter Friendly Version
05/26/15Tokai Pharmaceuticals Appoints Gerald Quirk as General Counsel and Executive Vice President, Business Operations
BOSTON--(BUSINESS WIRE)--May 26, 2015-- Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI), a biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally-driven diseases, today announced the appointment of Gerald Quirk as General Counsel and Executive Vice President, Business Operations. Mr. Quirk brings to Tokai more than twenty years of experience advancing the legal and business interests of public bio... 
Download PDFPrinter Friendly Version
05/12/15Tokai Pharmaceuticals to Present at the Bank of America Merrill Lynch 2015 Health Care Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 12, 2015-- Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI), a clinical-stage biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally driven diseases, today announced that management will provide a company overview at the Bank of America Merrill Lynch 2015 Health Care Conference in Las Vegas on Wednesday, May 13, 2015 at 8:00am PT. A live webcast of th... 
Download PDFPrinter Friendly Version
05/12/15Tokai Pharmaceuticals Reports First Quarter 2015 Financial Results
ARMOR3-SV Remains on Track to Begin 2Q 2015 with Topline Data Expected by End of 2016 BOSTON--(BUSINESS WIRE)--May 12, 2015-- Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI), a clinical-stage biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally driven diseases, today reported company highlights and financial results for the first quarter ended March 31, 2015. “Throughout the f... 
Download PDFPrinter Friendly Version
04/20/15Tokai Pharmaceuticals Announces Preclinical Results from the University of Maryland Showing Galeterone and Analogs Inhibit Pancreatic Cancer Cell Growth
BOSTON--(BUSINESS WIRE)--Apr. 20, 2015-- Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI), a clinical-stage biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally-driven diseases, today announced that scientists in the laboratory of Vincent Njar, PhD, at the University of Maryland School of Medicine presented preclinical data showing that galeterone and novel analogs of galeterone inhibited growth,... 
Download PDFPrinter Friendly Version
04/13/15Tokai Pharmaceuticals Announces the Appointment of Cheryl Cohen, Former Medivation Chief Commercial Officer, to its Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 13, 2015-- Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI), a clinical-stage biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally driven diseases, today announced the appointment of Cheryl Cohen, the former Chief Commercial Officer of Medivation, Inc., to its Board of Directors. “Cheryl brings significant commercial expertise to Tokai. As the former ... 
Download PDFPrinter Friendly Version
04/10/15Tokai Pharmaceuticals to Present at Upcoming Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 10, 2015-- Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI), a clinical-stage biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally-driven diseases, today announced that it will present at two upcoming conferences: Jodie Morrison, President and Chief Executive Officer, will participate in Cancer Advance Boston as part of a panel titled ... 
Download PDFPrinter Friendly Version
03/16/15Tokai Pharmaceuticals Announces Expansion to Collaboration with Qiagen on the Development of an AR-V7 Companion Diagnostic
Tokai and Qiagen Expect to Develop AR-V7 Clinical Trial Assay Prior to Opening ARMOR3-SV in 1H’15 Tokai Granted Exclusive Right to Qiagen’s Circulating Tumor Cell (CTC) Enrichment Technology for use with a Companion Diagnostic Paired with Galeterone CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 16, 2015-- Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI), a clinical-stage biopharmaceutical company focused on developing novel therapies for ... 
Download PDFPrinter Friendly Version
03/12/15Tokai Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 12, 2015-- Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI), a clinical-stage biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally driven diseases, today reported company highlights and financial results for the quarter and year ended December 31, 2014. “We are excited by the recent heightened attention on AR-V7 in prostate cancer and interest in o... 
Download PDFPrinter Friendly Version
03/02/15Tokai Pharmaceuticals to Present at the Cowen and Company 35th Annual Health Care Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 2, 2015-- Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI), a clinical-stage biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally driven diseases, today announced that Jodie Morrison, President and Chief Executive Officer, will provide a company overview at the Cowen and Company 35th Annual Health Care Conference in Boston, MA on Wednesday, March 4 at 8am ET. ... 
Download PDFPrinter Friendly Version
02/26/15Tokai Pharmaceuticals Announces Presentations at the 2015 Genitourinary Cancers Symposium
Tokai Presents Protocol and Rationale for ARMOR3-SV, a Pivotal Trial in Patients with AR-V7 Positive Castrate-Resistant Prostate Cancer and is Supporting a CME Session that will Discuss AR-V7 in Prostate Cancer CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 26, 2015-- Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI), a clinical-stage biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally driven diseases, tod... 
Download PDFPrinter Friendly Version
01/12/15Tokai Pharmaceuticals Provides Companion Diagnostic Update
ARMOR3-SV Remains On-Track to Begin in the First Half of the Year CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 12, 2015-- Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI), today announced that it has entered into an agreement with the Johns Hopkins University related to the development of a companion diagnostic to determine the AR-V7 status of patients with castration-resistant prostate cancer (CRPC) for use with the Company’s lead product, galeterone, w... 
Download PDFPrinter Friendly Version
01/09/15Stephen Buckley, Jr. Appointed to Tokai Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 9, 2015-- Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI), a clinical-stage biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally driven diseases, today announced that Stephen Buckley, Jr. has joined the company’s board of directors and will serve as chair of the audit committee. “We are delighted to welcome Steve to our board of directors,” stated ... 
Download PDFPrinter Friendly Version
Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts | Financial Tear Sheet Financial Tear Sheet